Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
19.90
-1.06 (-5.06%)
Feb 21, 2025, 4:00 PM EST - Market closed
Arrowhead Pharmaceuticals Revenue
Arrowhead Pharmaceuticals had revenue of $2.50M in the quarter ending December 31, 2024, a decrease of -29.60%. This brings the company's revenue in the last twelve months to $2.50M, down -98.62% year-over-year. In the fiscal year ending September 30, 2024, Arrowhead Pharmaceuticals had annual revenue of $3.55M, down -98.52%.
Revenue (ttm)
$2.50M
Revenue Growth
-98.62%
P/S Ratio
1,003.74
Revenue / Employee
$4,105
Employees
609
Market Cap
2.51B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 3.55M | -237.18M | -98.52% |
Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
Sep 30, 2020 | 87.99M | -80.80M | -47.87% |
Sep 30, 2019 | Pro | Pro | Pro |
Sep 30, 2018 | Pro | Pro | Pro |
Sep 30, 2017 | Pro | Pro | Pro |
Sep 30, 2016 | Pro | Pro | Pro |
Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ARWR News
- 3 days ago - Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions - Seeking Alpha
- 4 days ago - 20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset' - Market Watch
- 11 days ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results - Business Wire
- 12 days ago - Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics - Business Wire
- 4 weeks ago - Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600 - PRNewsWire
- 4 weeks ago - Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results - Business Wire
- 5 weeks ago - Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire